camptothecin has been researched along with n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianco, R; Cardone, C; Ciardiello, D; Ciardiello, F; Fenizia, F; Formisano, L; Lambiase, M; Martinelli, E; Martini, G; Morgillo, F; Napolitano, S; Normanno, N; Troiani, T; Vitagliano, D | 1 |
1 other study(ies) available for camptothecin and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Diphenylamine; Drug Synergism; ErbB Receptors; Female; Humans; Irinotecan; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |